Bayer Stroke Drug Breakthrough Results in €3 Billion Sales Forecast and 8% Stock Surge
Bayer has reported a major clinical trial success for its experimental stroke drug asundexian, a development analysts say could transform the German pharmaceutical giant’s fortunes. Following the announcement, Bayer’s shares surged nearly 9% in European trading, reflecting renewed investor confidence in its pipeline Investing.com Morningstar Invezz EconoTimes Alpha Spread. Trial Success The late‑stage OCEANIC‑STROKE Phase […]
Continue Reading